Success with ozanimod would justify $7.2 billion outlay for Receptos.
But drug will have boxed warning over suicidal ideation.
Trump calls pharma leaders to White House to discuss cutting taxes, regulations – and drug prices
Celgene continues with focus on autoimmune diseases.
Biotech specialises in autoimmune disorder drugs.
Earlier decision to reject drug reversed.
Otezla cheap and convenient, but less effective than rivals, says NICE.
Sales of dermatology drug are already mounting.